Abstract:
A process for the synthesis of β-hydroxy 3-17-(1H-benzimidazol-1-yl)androsta-5,16-diene is described, a compound also known as Galeterone and used in the treatment of prostate cancer, having the formula (6).
Abstract:
There is described a process for the industrial synthesis of 11-methylene-18- methyl-estr-4-en-3, 17-dione, a compound having the structure formula (I) depicted below: (Formula I) (I) useful as intermediate compound in the synthesis of the progestin compounds Desogestrel and Etonogestrel.
Abstract:
The present invention refers to a process for the industrial-scale preparation of 17β-hydroxy- 6β,7β;15β,16β-dimethylene-3-oxo-17α-pregn-4-ene-21-carboxylic acid y-lactone, known by the common name of Drospirenone, in the form of a fine powder without the use of mechanical grinding or micronization techniques, but rather exploiting a double change of crystalline form, from Crystalline Form I to Crystalline Form II and from Crystalline Form II to Crystalline Form I. The invention also refers to the new Crystalline Form II of Drospirenone obtained in the process.
Abstract:
The present invention relates to a process for the preparation of 21-(acetyloxy)-17-(1-oxopropoxy)-pregn-4-ene-3,20-dione (VI) having the formula below: Compound (VI) can be used as a precursor for the synthesis of Clascoterone, a steroid used for the treatment of acne.
Abstract:
The present invention relates to a novel process for the synthesis of abiraterone and in particular abiraterone acetate, a compound of formula (I) reported below: having pharmacological activity suitable for slowing down the progression of advanced stage prostate cancer. The process is characaterised by the fact that the intermediate triflation step is carried out on prasterone (DHEA) or its 3-acetate using Ar-N(OTf) 2 as the triflation reagent, but where Ar is not phenyl, and by the fact that the base used in this step is an alkali metal alcoholate.
Abstract:
The present invention relates to a process for preparing β-[(7α,17β)-17-hydroxy-7[9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nony]estra-1,3,5(10)-trien-3-yl]-boronic acid, also known as Fulvestrant-3-boronic acid or ZB716, whose structure is shown below: Formula (I).
Abstract:
The present invention relates to a process for preparing B-[(7α,17β)-17-hydroxy-7-[9-[(4,4,5,5,5~pentafluoropentyl)sulfinyl]nonyl]estra-1,3,5(10)-trien-3-yl]-boronic acid also known as Fulvestrant-3-boronic acid or ZB716, whose structure is reported below: Formula (I).
Abstract:
The present invention relates to a process for preparing B-[(7α,17β)-17-hydroxy-7-[9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl]estra-1,3,5(10)-trien-3-yl]-boronic acid, also known as Fulvestrant-3-boronic acid or ZB716, whose structure is reported below.
Abstract:
The present invention refers to a process for preparing (3α,5α)-3 -hydroxy-3 -methyl- pregnan-20-one, a compound also known as Ganaxolone, having the formula below: (I).
Abstract:
The present invention relates to a process for preparing (15α,16α,17β)-Estra-1,3,5(10)-triene-3,15,16,17-tetrol, also known as Estetrol, having the formula shown below: (I)